BACKGROUND: Currently, staging of head neck squamous cell carcinoma (HNSCC) is on the basis of primary tumor extension (cT), lymph node involvement (cN) and distant metastasis (cM). The aim of cancer staging was to improve diagnosis, prognosis and to compare outcome results. A new subgroup of oropharyngeal squamous cell carcinoma (OPSCC) induced by human papillomavirus (HPV) infection is reported to show an increasing incidence. These HPV-positive OPSCC show distinct molecular differences, specific p16 overexpression and a significantly better prognosis. Therefore, the aim of this study was to evaluate the prognostic influence of p16 expression in OPSCC and compare its relevance with the established prognostic markers cT and cN classification and the clinical stages I-IV. PATIENTS AND METHODS: Immunohistochemistry for p16 was carried out on the basis of a tissue microarray including 102 OPSCC patients with corresponding retrospective clinicopathological and follow-up data. RESULTS: p16 is the strongest independent prognostic marker in OPSCC, surpassing the significance of cT and cN classification as well as the clinical stages I-IV. Prognosis of p16-positive OPSCC of an advanced stage reached or even exceeded prognosis of the next clinically smaller conventionally staged group of tumors. CONCLUSION: p16 is the most relevant prognostic marker in OPSCC and should be considered for inclusion into the official staging system of HNSCC.
BACKGROUND: Currently, staging of head neck squamous cell carcinoma (HNSCC) is on the basis of primary tumor extension (cT), lymph node involvement (cN) and distant metastasis (cM). The aim of cancer staging was to improve diagnosis, prognosis and to compare outcome results. A new subgroup of oropharyngeal squamous cell carcinoma (OPSCC) induced by human papillomavirus (HPV) infection is reported to show an increasing incidence. These HPV-positive OPSCC show distinct molecular differences, specific p16 overexpression and a significantly better prognosis. Therefore, the aim of this study was to evaluate the prognostic influence of p16 expression in OPSCC and compare its relevance with the established prognostic markers cT and cN classification and the clinical stages I-IV. PATIENTS AND METHODS: Immunohistochemistry for p16 was carried out on the basis of a tissue microarray including 102 OPSCC patients with corresponding retrospective clinicopathological and follow-up data. RESULTS:p16 is the strongest independent prognostic marker in OPSCC, surpassing the significance of cT and cN classification as well as the clinical stages I-IV. Prognosis of p16-positive OPSCC of an advanced stage reached or even exceeded prognosis of the next clinically smaller conventionally staged group of tumors. CONCLUSION:p16 is the most relevant prognostic marker in OPSCC and should be considered for inclusion into the official staging system of HNSCC.
Authors: Christian Jacobi; Josepha Rauch; Jan Hagemann; Thomas Lautz; Maximilian Reiter; Philipp Baumeister Journal: Eur Arch Otorhinolaryngol Date: 2017-12-04 Impact factor: 2.503
Authors: Grace C Blitzer; Molly A Smith; Stephen L Harris; Randall J Kimple Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-15 Impact factor: 7.038
Authors: Andrew J Rosko; Andrew C Birkeland; Kevin F Wilson; Daniel G Muenz; Emily Bellile; Carol R Bradford; Jonathan B McHugh; Matthew E Spector Journal: Otolaryngol Head Neck Surg Date: 2016-03-15 Impact factor: 3.497
Authors: Christos Loizou; Göran Laurell; David Lindquist; Charlotte Öfverman; Kristina Stefansson; Karin Nylander; Katarina Olofsson Journal: Oncol Lett Date: 2015-10-02 Impact factor: 2.967
Authors: N L Hoefling; J B McHugh; E Light; B Kumar; H Walline; M Prince; C Bradford; T E Carey; S K Mukherji Journal: AJNR Am J Neuroradiol Date: 2013-01-31 Impact factor: 3.825
Authors: Samuel Barasch; Pranshu Mohindra; Kenneth Hennrick; Gregory K Hartig; Paul M Harari; David T Yang Journal: Am J Surg Pathol Date: 2016-09 Impact factor: 6.394